These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 15681915

  • 1. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
    Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD.
    J Clin Gastroenterol; 2005 Feb; 39(2):168-71. PubMed ID: 15681915
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis.
    Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA.
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1165-9. PubMed ID: 10524648
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
    Rabahi N, Chrétien Y, Gaouar F, Wendum D, Serfaty L, Chazouillères O, Corpechot C, Poupon R.
    Gastroenterol Clin Biol; 2010 Oct; 34(4-5):283-7. PubMed ID: 20417047
    [Abstract] [Full Text] [Related]

  • 4. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD.
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [Abstract] [Full Text] [Related]

  • 5. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD.
    Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
    [Abstract] [Full Text] [Related]

  • 6. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study.
    Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM, Rossi SS, Hofmann AF, Baldus WP.
    Hepatology; 1995 Oct; 22(4 Pt 1):1158-62. PubMed ID: 7557866
    [Abstract] [Full Text] [Related]

  • 7. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.
    Treiber G, Malfertheiner P.
    J Clin Gastroenterol; 2005 Oct; 39(9):837-8; author reply 838. PubMed ID: 16145353
    [No Abstract] [Full Text] [Related]

  • 8. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R.
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [Abstract] [Full Text] [Related]

  • 9. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy.
    Chazouillères O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R.
    Hepatology; 1998 Aug; 28(2):296-301. PubMed ID: 9695990
    [Abstract] [Full Text] [Related]

  • 10. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
    Hazzan R, Tur-Kaspa R.
    J Clin Gastroenterol; 2010 Aug; 44(5):371-3. PubMed ID: 19881358
    [Abstract] [Full Text] [Related]

  • 11. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR, Dutch PBC Study Group.
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [Abstract] [Full Text] [Related]

  • 12. Mycophenolate mofetil for primary biliary cirrhosis--convergent thinking.
    Altschuler EL.
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):587. PubMed ID: 10833107
    [No Abstract] [Full Text] [Related]

  • 13. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis.
    Ozaslan E, Efe C, Heurgué-Berlot A, Kav T, Masi C, Purnak T, Muratori L, Ustündag Y, Bresson-Hadni S, Thiéfin G, Schiano TD, Wahlin S, Muratori P.
    Clin Gastroenterol Hepatol; 2014 May; 12(5):863-9. PubMed ID: 24076417
    [Abstract] [Full Text] [Related]

  • 14. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.
    Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW.
    Am J Gastroenterol; 2013 Jun; 108(6):933-41. PubMed ID: 23649186
    [Abstract] [Full Text] [Related]

  • 15. Natural history of pruritus in primary biliary cirrhosis.
    Talwalkar JA, Souto E, Jorgensen RA, Lindor KD.
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
    [Abstract] [Full Text] [Related]

  • 16. [Treatment of primary biliary cirrhosis with ursodeoxycholic acid].
    Nikolovska D, Vasilev P, Mikhova A.
    Vutr Boles; 2000 Jul; 32(1):25-7. PubMed ID: 11195193
    [Abstract] [Full Text] [Related]

  • 17. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
    Corpechot C, Chazouillères O, Poupon R.
    J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
    [Abstract] [Full Text] [Related]

  • 18. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: is a double dosage worthwhile?
    Angulo P, Jorgensen RA, Lindor KD.
    Am J Gastroenterol; 2001 Nov; 96(11):3152-7. PubMed ID: 11721764
    [Abstract] [Full Text] [Related]

  • 19. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA, Sanai FM, Swain MG.
    Aliment Pharmacol Ther; 2006 Sep 01; 24(5):813-20. PubMed ID: 16918885
    [Abstract] [Full Text] [Related]

  • 20. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P, Batts KP, Therneau TM, Jorgensen RA, Dickson ER, Lindor KD.
    Hepatology; 1999 Mar 01; 29(3):644-7. PubMed ID: 10051462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.